Risk factors for nosebleed coming back in adults
Part of Ear, nose & throat, Lungs & breathing clinical trials.
This study looks at adults who went to the emergency room for a nosebleed to find out why some people get another nosebleed later. It may help doctors better understand and prevent repeat nosebleeds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You went to the emergency room for a nosebleed between January 2022 and July 2023.
- You are 18 years old or older.
- You agree to let the researchers use your medical information.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at different management strategies for severe nosebleeds when the initial packing method has not worked for over 48 hours. It also measures the cost/benefit of these approaches to help improve care.
This study tests whether applying beta-sitosterol (a natural plant substance) to the inside of the nose helps stop nosebleeds better than plain Vaseline. If you have frequent nosebleeds without a known cause, this trial may offer a simple local treatment option.
This study tests whether a natural orange peel extract spray can help stop nosebleeds in children. If your child gets nosebleeds from the front of the nose and has no other health problems with their blood or nose, this may be an option to explore.
This trial tests a new nose spray (TOR-582) to reduce nosebleeds in people with HHT. If you have moderate nosebleeds, this treatment might help decrease how often and how long they last.
This trial compares two gels—hyaluronic acid and petroleum jelly—to see which works better at stopping nosebleeds from the front of the nose. The goal is to find a simpler, non-invasive treatment that reduces bleeding and speeds healing.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
Hear when a new Epistaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.